Search
for
Sort by
Research 30 of 581
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- Ruxolitinib for the treatment of severe alopecia areata
- Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
- Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
- Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
- Ruxolitinib found to cause eyelash growth: a case report
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
- Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
- Alopecia Universalis and Chronic Graft-vs-Host Disease Treated With Ruxolitinib
- Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
- Delayed granulomatous eruption of the nose associated with ruxolitinib
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation
- Ruxolitinib: A novel molecule in the management of dermatological disorders
- Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with <i>AIRE</i> gene mutation (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy, APECED syndrome) treated with ruxolitinib
- A Successful Treatment of Alopecia Universalis with Ruxolitinib
- A Single Subcutaneous Dose of BMD-1141 Stimulates Hair Regrowth Comparable to Daily, High-Dose Ruxolitinib in a Mouse Model of Alopecia Areata.
- BH02 Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with the <i>AIRE</i> gene mutation treated with ruxolitinib
- Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
- ISID1108 - Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata.
- 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
- Topical Ruxolitinib for the Treatment of Alopecia Universalis
- A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata
- Topical Ruxolitinib for Folliculitis Decalvans
- Fast clinical response with topical ruxolitinib in the management of non-segmental vitiligo detected by VISIA<sup>®</sup> analysis system
- Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B